Valuation: Novartis AG

Market Cap 298B 258B 241B 220B 415B 28,407B 422B 2,826B 1,109B 14,211B 1,118B 1,094B 47,332B P/E 2026 *
22.2x
P/E 2027 * 19x
Enterprise Value 331B 287B 268B 245B 461B 31,565B 468B 3,140B 1,232B 15,791B 1,243B 1,216B 52,594B EV / Sales 2026 *
5.75x
EV / Sales 2027 * 5.33x
Free-Float
91.66%
Yield 2026 *
2.79%
Yield 2027 * 2.91%
1 day+0.26%
1 week+1.44%
Current month+0.34%
1 month+1.93%
3 months+9.94%
6 months+2.91%
Current year+15.55%
1 week 132.28
Extreme 132.28
136.46
1 month 131.28
Extreme 131.28
140.92
Current year 116.12
Extreme 116.12
144.08
1 year 101.42
Extreme 101.42
144.08
3 years 94.56
Extreme 94.56
144.08
5 years 94.56
Extreme 94.56
144.08
10 years 62.12
Extreme 62.12
144.08
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Compliance Officer 58 2025-04-13
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.26%+1.44% - - 296B
+3.90%+9.86%+96.91%+136.30% 1,057B
+0.99%+2.91%+51.05%+52.06% 625B
+0.78%+1.17%+25.21%+63.74% 435B
+1.58%+4.80%+51.42%+39.79% 363B
+0.65%+1.85%+34.81%+39.99% 296B
+0.79%+4.26%+9.78%+7.42% 249B
+1.52%+10.12%+44.75%+59.20% 222B
+0.34%+1.27%-5.23%-50.94% 209B
-0.11%+1.46%+11.43%+66.32% 165B
Average +1.07%+3.10%+35.57%+45.99% 402.31B
Weighted average by Cap. +1.66%+4.76%+51.76%+67.92%

Financials

2026 *2027 *
Net sales 57.58B 49.85B 46.6B 42.59B 80.25B 5,492B 81.5B 546B 214B 2,748B 216B 212B 9,151B 61.12B 52.91B 49.46B 45.2B 85.18B 5,830B 86.51B 580B 228B 2,916B 230B 225B 9,713B
Net income 13.78B 11.93B 11.15B 10.19B 19.2B 1,314B 19.5B 131B 51.31B 658B 51.74B 50.62B 2,190B 15.36B 13.3B 12.43B 11.36B 21.4B 1,465B 21.74B 146B 57.18B 733B 57.67B 56.41B 2,441B
Net Debt 33.11B 28.67B 26.79B 24.49B 46.15B 3,158B 46.87B 314B 123B 1,580B 124B 122B 5,262B 27.82B 24.08B 22.51B 20.57B 38.77B 2,653B 39.37B 264B 104B 1,327B 104B 102B 4,420B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
26-08-10 €136.46 +0.26% 1,191
26-08-07 €136.10 +2.89% 768
26-08-06 €132.28 -0.26% 630
26-08-05 €132.62 -1.32% 1,726
26-08-04 €134.40 -0.09% 540
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
156.70USD
Average target price
154.14USD
Spread / Average Target
-1.64%

Quarterly revenue - Rate of surprise